Factors associated with the glucose-lowering effect of vildagliptin identified from the results of the oral glucose tolerance test in Japanese patients with type 2 diabetes

Endocrine Journal

Volumn 60, Issue 1, 2013, Pages 45-49

  Nakamura, Akinobu ^a   Terauchi, Yasuo ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

Glucose stimulated insulin secretion; Insulin sensitivity; Oral glucose tolerance test; Vildagliptin

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; GLUCOSE; HEMOGLOBIN A1C; INSULIN; SULFONYLUREA; VILDAGLIPTIN;

AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN RELEASE; INSULIN SENSITIVITY; JAPANESE; MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PATIENT CODING; PATIENT SATISFACTION;

ADAMANTANE; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FEMALE; FOLLOW-UP STUDIES; GLUCOSE TOLERANCE TEST; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; JAPAN; MALE; MIDDLE AGED; NITRILES; PYRROLIDINES; TREATMENT OUTCOME;

EID: 84873511338     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.EJ12-0208     Document Type: Article

References (16)

1. Stamataros G, Schneider SH (2011) Vildagliptin in the treatment of type 2 diabetes mellitus. Expert Opin Pharmacother 12: 1967-1973.
2. Ahrén B, Pacini G, Foley JE, Schweizer A (2005) Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year. Diabetes Care 28: 1936-1940.
3. D'Alessio DA, Denney AM, Hermiller LM, Prigeon RL, Martin JM, et al. (2009) Treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin improves fasting islet-cell function in subjects with type 2 diabetes. J Clin Endocrinol Metab 94: 81-88.
4. Balas B, Baig MR, Watson C, Dunning BE, Ligueros-Saylan M, et al. (2007) The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after singledose administration in type 2 diabetic patients. J Clin Endocrinol Metab 92:1249-1255.
5. The Committee of Japan Diabetes Society on the Diagnostic Criteria of Diabetes Mellitus (2010) Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. J Diabetes Invest 1: 212-228.
6. Matsuda M, DeFronzo RA (1999) Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 22: 1462-1470.
7. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, et al. (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412-419.
8. Onishi Y, Hayashi T, Kogawa Sato K, Ogihara T, Kuzuya N, et al. (2010) Fasting tests of insulin secretion and sensitivity predict future prediabetes in Japanese with normal glucose tolerance. J Diabetes Invest 1: 191- 195.
9. Utzschneider KM, Prigeon RL, Faulenbach MV, Tong J, Carr DB, et al. (2009) Oral disposition index predicts the development of future diabetes above and beyond fasting and 2-h glucose levels. Diabetes Care 32: 335-341.
10. Meier JJ, Menge BA, Breuer TG, Müller CA, Tannapfel A, et al. (2009) Functional assessment of pancreatic beta-cell area in humans. Diabetes 58: 1595-1603.
11. Sathananthan A, Man CD, Micheletto F, Zinsmeister AR, Camilleri M, et al. (2010) Common genetic variation in GLP1R and insulin secretion in response to exogenous GLP-1 in nondiabetic subjects: a pilot study. Diabetes Care 33: 2074-2076.
12. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, et al. (2003) Beta-cell deficit and increased betacell apoptosis in humans with type 2 diabetes. Diabetes 52: 102-110.
13. Sato K, Nakamura A, Shirakawa J, Muraoka T, Togashi Y, et al. (2012) Impact of the dipeptidyl peptidase-4 inhibitor vildagliptin on glucose tolerance and betacell function and mass in insulin receptor substrate-2-knockout mice fed a high-fat diet. Endocrinology 153: 1093-1102.
14. Foley JE, Bunck MC, Möller-Goede DL, Poelma M, Nijpels G, et al. (2011) Beta cell function following 1 year vildagliptin or placebo treatment and after 12 week washout in drug-naive patients with type 2 diabetes and mild hyperglycaemia: a randomised controlled trial. Diabetologia 54: 1985-1991.
15. Stancáková A, Javorský M, Kuulasmaa T, Haffner SM, Kuusisto J, et al. (2009) Changes in insulin sensitivity and insulin release in relation to glycemia and glucose tolerance in 6,414 Finnish men. Diabetes 58: 1212-1221.
16. Muniyappa R, Lee S, Chen H, Quon MJ (2008) Current approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usage. Am J Physiol Endocrinol Metab 294: E15-26.